Sugi Predict

Sugi Predict / Targets / GLRX3

GLRX3

Glutaredoxin-3 · O76003 · GLRX3 on Sugi Atlas →

0 patent compounds predicted against GLRX3, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to GLRX3 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Paracetamol Study in Patients With Low Muscle Mass PHASE4UNKNOWN
Treatment of Cognitive and Negative Symptoms in Schizophrenia With N-acetylcysteine PHASE4COMPLETED
Cysteine Supplementation in Critically Ill Neonates PHASE2/PHASE3UNKNOWN
Neurobiology of a Mutation in Glycine Metabolism in Psychotic Disorders PHASE2COMPLETED
Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy PHASE2ACTIVE_NOT_RECRUITING
N-Acetylcysteine for Neuroprotection in Parkinson's Disease PHASE1/PHASE2COMPLETED
Creatine Therapy for Huntington's Disease PHASE1/PHASE2COMPLETED
Sulfasalazine in Decreasing Opioids Requirements in Breast Cancer Patients PHASE2COMPLETED
A Study of Oxidative Pathways in MS Fatigue PHASE2COMPLETED
EPI-743 in Cobalamin C Defect: Effects on Visual and Neurological Impairment PHASE2COMPLETED
GM604 Phase 2A Randomized Double-blind Placebo Controlled Pilot Trial in Amyotrophic Lateral Disease (ALS) PHASE2COMPLETED
Open-Trial of EPI-743 for Adults With Tourette Syndrome PHASE1COMPLETED
N-acetylcysteine (NAC) for Improving Cognitive Dysfunction in Schizophrenia PHASE1COMPLETED
The Effects of a Glutathione Precursor (FT061452),on Serum and Intracellular Glutathione Levels PHASE1COMPLETED
Tolerability of Enteral NAC in Infants PHASE1NOT_YET_RECRUITING
Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine EARLY_PHASE1COMPLETED
Changes in Glutamatergic Neurotransmission of Severe TBI Patients EARLY_PHASE1SUSPENDED
Effect of Sulfur Amino Acid Depletion and Acetaminophen on Plasma Glutatione nanCOMPLETED
Integrins and Protocadherins in Glutamatergic Circuits: Identification of Common Signaling Pathways and Molecular Targets in Anxiety and Major Depressive Disorders (GAPsy) nanUNKNOWN
Acute Glycine Pharmacodynamic Study nanCOMPLETED
Transcriptomic Profile of Patients Treated With Different Modalities of Spinal Cord Stimulation nanUNKNOWN
Neurometabolic Profile of Individuals With Primary Mitochondrial Disease nanRECRUITING
Natural History Study of FDXR Mutation-related Mitochondriopathy nanCOMPLETED
Evaluation of Mitochondrial Enzyme Activity in Cesarean Section Patients nanUNKNOWN
Thiol/Disulphide Homeostasis in Unexplained Infertility nanCOMPLETED
NAC Supplementation and Skeletal Muscle Performance nanCOMPLETED
Supplementation of Oral Reduced Glutathione in Pediatric Cystic Fibrosis Patients nanCOMPLETED
Using Next-generation Sequencing in the Diagnosis of Epilepsy and/or Intellectual Disability in a Pediatric Cohorte nanCOMPLETED
Genetic Variants Associated With Adolescent Suicide Attempts nanCOMPLETED
Consortium On Risk for Early-onset Parkinson's Disease (CORE PD) nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a GLRX3 binder may also engage these)

ProteinNameSimilarity
Q9JLZ1 — 1.000 Q9JLZ1 →
Q9CQM9 — 0.999 Q9CQM9 →
Q58DA7 — 0.998 Q58DA7 →
Q28ID3 — 0.987 Q28ID3 →
Q5XJ54 — 0.980 Q5XJ54 →
Q6DBT3 — 0.942 Q6DBT3 →
Q9CQM5 — 0.942 Q9CQM5 →
T1SH39 — 0.935 T1SH39 →
A6QLU8 — 0.933 A6QLU8 →
Q6DKJ4 — 0.927 Q6DKJ4 →
Q5R514 — 0.927 Q5R514 →
Q2KIK0 — 0.927 Q2KIK0 →
Q28DS0 — 0.926 Q28DS0 →
P19356 — 0.926 P19356 →
Q5R8R4 — 0.924 Q5R8R4 →
B9N1F9 — 0.924 B9N1F9 →
UMPS Uridine 5'-monophosphate synthase 0.924 landscape →
Q503L9 — 0.923 Q503L9 →
Q5RFI8 — 0.923 Q5RFI8 →
Q5R4R2 — 0.923 Q5R4R2 →
Q5RC61 — 0.923 Q5RC61 →
Q8JGT5 — 0.923 Q8JGT5 →
Q5RDM4 — 0.922 Q5RDM4 →
Q9ZR41 — 0.922 Q9ZR41 →
P97346 — 0.922 P97346 →
B2RZ27 — 0.922 B2RZ27 →
P13439 — 0.922 P13439 →
Q61316 — 0.922 Q61316 →
Q4KM49 — 0.922 Q4KM49 →
Q91VW3 — 0.922 Q91VW3 →